Losartan protects the rat kidney from ischemic injury
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8743528
Knihovny.cz E-resources
- MeSH
- Antihypertensive Agents therapeutic use MeSH
- Biphenyl Compounds therapeutic use MeSH
- Hypertension complications genetics physiopathology MeSH
- Imidazoles therapeutic use MeSH
- Rats, Inbred Strains MeSH
- Ischemia prevention & control MeSH
- Creatinine urine MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Losartan MeSH
- Survival Rate MeSH
- Kidney Diseases etiology prevention & control MeSH
- Proteinuria prevention & control MeSH
- Renal Circulation drug effects MeSH
- Tetrazoles therapeutic use MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antihypertensive Agents MeSH
- Biphenyl Compounds MeSH
- Imidazoles MeSH
- Creatinine MeSH
- Losartan MeSH
- Tetrazoles MeSH
Administration of losartan (L), an angiotensin II receptor antagonist, at a daily dose of 3 mg/kg body wt, lowered systolic blood pressure (SBP) in both the Prague hypertensive rat and the Prague normotensive rat (PNR). Proteinuria was markedly reduced in both strains by L. Seven days after kidney ischemia due to bilateral clamping of both renal arteries for 45 minutes, the renal function (endogenous creatinine clearance, sodium, potassium, and urea excretion rates) was completely normal in L-treated PHR and PNR, whereas distinct deterioration was observed in untreated animals. The survival rate after kidney ischemia was significantly improved by L in both PHR and PNR. Thus, L had a significant blood pressure-lowering action in both strains and exerted a distinct renal protective effect from kidney ischemia.
Research on Experimental Hypertension in Prague (1966-2009)
